ONYX PHARMACEUTICALS INC 4
4 · ONYX PHARMACEUTICALS INC · Filed Oct 3, 2013
Insider Transaction Report
Form 4
WOOD JULIANNA R
VP, Corp. Communication/I.R.
Transactions
- Disposition to Issuer
Common Stock
2013-10-01$125.00/sh−9,550$1,193,750→ 0 total - Disposition to Issuer
Stock Options
2013-10-01−2,555→ 0 totalExercise: $30.28From: 2011-03-31Exp: 2020-03-31→ Common Stock (2,555 underlying) - Disposition to Issuer
Stock Options
2013-10-01−2,549→ 0 totalExercise: $30.28From: 2011-03-31Exp: 2020-03-31→ Common Stock (2,549 underlying) - Disposition to Issuer
Stock Options
2013-10-01−3,069→ 0 totalExercise: $37.68From: 2013-03-30Exp: 2022-03-30→ Common Stock (3,069 underlying) - Disposition from Tender
Common Stock
2013-10-01$125.00/sh−200$25,000→ 0 total(indirect: By Trust) - Disposition to Issuer
Stock Options
2013-10-01−2,618→ 0 totalExercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (2,618 underlying) - Disposition from Tender
Common Stock
2013-10-01$125.00/sh−9,824$1,228,000→ 9,550 total - Disposition to Issuer
Stock Options
2013-10-01−5,403→ 0 totalExercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (5,403 underlying) - Disposition to Issuer
Stock Options
2013-10-01−7,000→ 0 totalExercise: $88.86From: 2014-03-28Exp: 2023-03-28→ Common Stock (7,000 underlying) - Disposition to Issuer
Stock Options
2013-10-01−13,222→ 0 totalExercise: $37.68From: 2013-03-30Exp: 2022-03-30→ Common Stock (13,222 underlying)
Footnotes (2)
- [F1]These restricted stock awards were cancelled at the effective time of the merger (the "Merger") pursuant to the Agreement and Plan of Merger, dated August 24, 2013, by and among Onyx Pharmaceuticals, Inc. ("Onyx"), Amgen Inc. and Arena Acquisition Company (the "Merger Agreement") in exchange for an aggregate cash payment equal to the number of shares of Onyx's common stock underlying such restricted stock awards multiplied by the per share purchase price of $125.00. Reflects the forfeiture of 2,025 performance based restricted stock units.
- [F2]Represents options to purchase Onyx's common stock that were subject to vesting over time but were cancelled in the Merger in exchange for a cash payment in the amount by which the per share purchase price of $125.00 exceeded the exercise price of the option as of the effective time of the Merger.